{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:44:11Z","timestamp":1790664251217,"version":"4.1.0"},"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2016,5,10]],"date-time":"2016-05-10T00:00:00Z","timestamp":1462838400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0155273","type":"journal-article","created":{"date-parts":[[2016,5,10]],"date-time":"2016-05-10T13:26:46Z","timestamp":1462886806000},"page":"e0155273","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["Effect of Pioglitazone in Preventing In-Stent Restenosis after Percutaneous Coronary Intervention in Patients with Type 2 Diabetes: A Meta-Analysis"],"prefix":"10.1371","volume":"11","author":[{"given":"Shi-jie","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao-shuang","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-xian","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-ye","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,5,10]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S0002-8703(99)70146-8","article-title":"Primary stenting in acute myocardial infarction: influence of diabetes mellitus in angiographic results and clinical outcome","volume":"138","author":"JA Silva","year":"1999","journal-title":"Am Heart J"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/ccd.22369","article-title":"Comparison of three-year clinical outcomes between sirolimus-versus paclitaxel-eluting stents in diabetic patients: prospective randomized multicenter trial","volume":"76","author":"SJ Hong","year":"2010","journal-title":"Catheter Cardiovasc Interv"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1161\/01.ATV.0000251021.28725.e8","article-title":"Pioglitazone inhibits in-stent restenosis in atherosclerotic rabbits by targeting transforming growth factor-beta and MCP-1","volume":"27","author":"M Joner","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.atherosclerosis.2007.08.030","article-title":"Pioglitazone attenuates neointimal thickening via suppression of the early inflammatory response in a porcine coronary after stenting","volume":"197","author":"T Kasai","year":"2008","journal-title":"Atherosclerosis"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2174\/1570161111311040004","article-title":"Therapies Targeting Inflammation After Stent Implantation","volume":"11","author":"H Okura","year":"2013","journal-title":"Curr Vasc Pharmacol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"SE Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jama.298.10.1180","article-title":"Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials","volume":"298","author":"AM Lincoff","year":"2007","journal-title":"Jama"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1001\/jama.283.17.2228","article-title":"Withdrawal of Troglitazone and Cisapride","volume":"283","author":"JE Henney","year":"2000","journal-title":"Jama"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jcin.2010.10.016","article-title":"Role of pioglitazone in the prevention of restenosis and need for revascularization after bare-metal stent implantation: a meta-analysis","volume":"4","author":"D Patel","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1161\/01.CIR.0000129767.45513.71","article-title":"Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy","volume":"109","author":"I Moussa","year":"2004","journal-title":"Circulation"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.diabet.2007.09.002","article-title":"Coronary in-stent restenosis in diabetic patients after implantation of sirolimus or paclitaxel drug-eluting coronary stents","volume":"34","author":"M Kitoga","year":"2008","journal-title":"Diabetes Metab"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1136\/hrt.2005.075960","article-title":"Multiple predictors of coronary restenosis after drug-eluting stent implantation in patients with diabetes","volume":"92","author":"SJ Hong","year":"2006","journal-title":"Heart"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1517\/14656566.2014.948844","article-title":"A Pharmacological inhibition of coronary restenosis: systemic and local approaches","volume":"15","author":"E Guerra","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"D Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"ref15","unstructured":"Higgins J, Green S (2010) Cochrane handbook for systematic reviews of interventions version 5.0. 2 [updated September 2009]. The Cochrane Collaboration, 2009. Available: www.cochrane-handbook.org<\/ext-link>."},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"CB Begg","year":"1994","journal-title":"Biometrics"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.clinthera.2012.02.024","article-title":"Effects of Thiazolidinediones on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After Drug-Eluting Stent Implantation: A Retrospective Cohort Study Using the National Health Insurance Database in Taiwan","volume":"34","author":"H Yeh","year":"2012","journal-title":"Clinical Therapeutics"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jjcc.2009.01.011","article-title":"Improved cardiac function after sirolimus-eluting stent placement in diabetic patients by pioglitazone: Combination therapy with statin","volume":"53","author":"T Ozawa","year":"2009","journal-title":"Journal of Cardiology"},{"key":"ref19","first-page":"139","article-title":"Thiazolidinedione treatment attenuates diffuse neointimal hyperplasia in restenotic lesions after coronary stent implantation in type 2 diabetic patients: An intravascular ultrasound study","volume":"45","author":"T Takagi","year":"2005","journal-title":"Journal of Cardiology"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S1056-8727(01)00190-8","article-title":"Impact of insulin resistance on neointimal tissue proliferation after coronary stent implantationIntravascular ultrasound studies","volume":"16","author":"T Takagi","year":"2002","journal-title":"Journal of Diabetes and its Complications"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.3349\/ymj.2013.54.6.1313","article-title":"Effects of low dose pioglitazone on restenosis and coronary atherosclerosis in diabetic patients undergoing drug eluting stent implantation","volume":"54","author":"HW Lee","year":"2013","journal-title":"Yonsei Med J"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"E1914","DOI":"10.1016\/S0735-1097(11)61914-1","article-title":"Cellular and molecular changes associated with inhibitory effect of pioglitazone on neointimal growth in patients with type 2 diabetes after zotarolimus-eluting stent implantation","volume":"57","author":"CM Ahn","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jcin.2009.04.007","article-title":"A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study)","volume":"2","author":"T Takagi","year":"2009","journal-title":"JACC Cardiovasc Interv"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s00380-006-0951-z","article-title":"Efficacy and safety of low-dose pioglitazone after primary coronary angioplasty with the use of bare metal stent in patients with acute myocardial infarction and with type 2 diabetes mellitus or impaired glucose tolerance","volume":"22","author":"J Yokoyama","year":"2007","journal-title":"Heart Vessels"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2337\/diacare.29.01.06.dc05-1170","article-title":"A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes","volume":"29","author":"K Nishio","year":"2006","journal-title":"Diabetes Care"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.1016\/S0002-8703(03)00146-7","article-title":"Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study","volume":"146","author":"T Takagi","year":"2003","journal-title":"Am Heart J"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000051263","article-title":"Interrater reliability of the modified Jadad quality scale for systematic reviews of Alzheimer's disease drug trials","volume":"12","author":"M Oremus","year":"2001","journal-title":"Dement Geriatr Cogn Disord"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0735-1097(97)00450-6","article-title":"In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia","volume":"31","author":"R Kornowski","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1253\/circj.CJ-13-0236","article-title":"Endothelial loss and repair in the vascular complications of diabetes: pathogenetic mechanisms and therapeutic implications","volume":"77","author":"RE Gilbert","year":"2013","journal-title":"Circ J"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.amjcard.2009.10.064","article-title":"Long-term prognostic value of preprocedural C-reactive protein after drug-eluting stent implantation","volume":"105","author":"C Delhaye","year":"2010","journal-title":"Am J Cardiol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.2337\/diacare.26.9.2493","article-title":"Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect","volume":"26","author":"N Satoh","year":"2003","journal-title":"Diabetes Care"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMra041001","article-title":"Thiazolidinediones","volume":"351","author":"H Yki-J\u00e4rvinen","year":"2004","journal-title":"N Engl J Med"},{"key":"ref33","article-title":"Role of pleiotropic properties of peroxisome proliferator-activated receptors in the heart: focus on the non-metabolic effects in cardiac protection","author":"E Barlaka","year":"2015","journal-title":"Cardiovasc Ther"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1253\/circj.CJ-13-0647","article-title":"Pleiotropic effects of peroxisome proliferator-activated receptor gamma and delta in vascular diseases","volume":"77","author":"WS Cheang","year":"2013","journal-title":"Circ J"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1253\/circj.CJ-14-0964","article-title":"Pioglitazone increases circulating microRNA-24 with decrease in coronary neointimal hyperplasia in type 2 diabetic patients- optical coherence tomography analysis","volume":"79","author":"SJ Hong","year":"2015","journal-title":"Circ J"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/hrt.2005.061622","article-title":"Drug eluting stents: an updated meta-analysis of randomised controlled trials","volume":"92","author":"C Roiron","year":"2006","journal-title":"Heart"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1146\/annurev.med.55.091902.105243","article-title":"Drug-eluting stents","volume":"55","author":"TC Wood","year":"2004","journal-title":"Annu Rev Med"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.amjcard.2005.07.043","article-title":"Impact of diabetes mellitus on angiographic and clinical outcomes in the drug-eluting stents era","volume":"96","author":"TH Yang","year":"2005","journal-title":"Am J Cardiol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0735-1097(98)00286-1","article-title":"The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation","volume":"32","author":"A Abizaid","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.2337\/diacare.28.7.1547","article-title":"A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia","volume":"28","author":"RB Goldberg","year":"2005","journal-title":"Diabetes Care"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/jama.299.13.1561","article-title":"Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial","volume":"299","author":"SE Nissen","year":"2008","journal-title":"Jama"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jcmg.2011.08.007","article-title":"Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET\/CT imaging study of carotid artery and ascending aorta","volume":"4","author":"M Mizoguchi","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.jcmg.2013.09.004","article-title":"Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET\/CT imaging","volume":"6","author":"Y Nitta","year":"2013","journal-title":"JACC Cardiovasc Imaging"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1161\/ATVBAHA.112.300346","article-title":"Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors","volume":"33","author":"A Saremi","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/dom.12608","article-title":"Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes","volume":"18","author":"E Erdmann","year":"2016","journal-title":"Diabetes Obes Metab"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0155273","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T08:06:28Z","timestamp":1589011588000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0155273"}},"subtitle":[],"editor":[{"given":"Kevin J.","family":"Croce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,5,10]]},"references-count":45,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2016,5,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0155273","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,10]]}}}